Incidence and predictors of virologic failure of antiretroviral triple- drug therapy in a community-based cohort

AIDS Research and Human Retroviruses

Volumn 15, Issue 18, 1999, Pages 1631-1638

  Paris, Daniel ^a   Ledergerber, Bruno ^a   Weber, Rainer ^a   Jost, Josef ^a   Flepp, Markus ^a   Opravil, Milos ^a   Ruef, Christian ^a   Zimmerli, Stefan ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDANOSINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INCIDENCE; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY; SAQUINAVIR; STAVUDINE; SWITZERLAND; TREATMENT FAILURE; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0032787511     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299309676     Document Type: Article

References (19)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, and Battegay M: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997;315:1194-1199.
3. Fatkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, and Salzberger B: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-F116.
4. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, and Grant RM: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-F43.
5. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danher S, Boucher C, Molla A, and Leonard JM: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-F14.
6. Casado JL, Perez-Elías MJ, Antela A, Sabido R, Martí-Belda P, Dronda F, Blazquez J, and Quereda Q: Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998;12:F131-F135.
7. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, and Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
8. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, and Kahn JO: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-311.
9. Ledergerber B, von Overbeck J, Egger M, and Luthy R: The Swiss HIV Cohort Study: Rationale, organization and selected base-line characteristics. Soz Praventivmed 1994;39:387-394.
10. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 1995;374:569-571.
11. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, and Richman DD: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
12. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C, and Wainberg MA: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:1390-1392.
13. Noble S and Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996;52:93-112.
14. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, and Leonard J: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-549.
15. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, and Volberding PA: Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA panel. JAMA 1998;280:78-86.
16. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, and Hamilton JD: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997;126:939-945.
17. Kaufmann D, Pantaleo G, Sudre P, and Telenti A: CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998;351:723-724.
18. Mellors J, Japour AJ, Cameron DW, Farthing C, Cohen C, Markowitz M, Poretz D, Follansbee S, Ho D, McMahon D, Berg J, Nieves J, Xu Y, Rode R, Salgo M, Leonard J, and Sun E: Ritonavir (RTV)-saquinavir (SQV) in protease inhibitor-naive patients after 72 weeks. In: 12th World AIDS Conference. Geneva, Switzerland. Geneva, 1998. [Abstract 12295]
19. Perry CM and Noble S: Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998; 55:461-168.